Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study

Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study

Objective: This study was conducted to investigate the safety, tolerability and pharmacokinetics (PK) of WXFL10203614 after single and multiple oral doses in healthy Chinese subjects.Methods: A single-center, randomized, double-blind, placebo-controlled phase Ⅰ study was performed on healthy Chinese...

Full description

Bibliographic Details
Main Authors: Kai Huang, Ying Ding, Linling Que, Nannan Chu, Yunfei Shi, Zhenzhong Qian, Wei Qin, Yuanxin Chen, Xianghong Gu, Jiakun Wang, Zhiwei Zhang, Jianguo Xu, Qing He
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
WXFL10203614
pharmacokinetics
JAK1 inhibitor
rheumatoid arthritis
first-in-human
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1057949/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1057949/full

Similar Items